Time filter

Source Type

Jacksonville Beach, FL, United States

Jacksonville University is a private university in Jacksonville, Florida, United States. The school was founded in 1934 as a two-year college and was known as Jacksonville Junior College until 1958, when it shifted its focus to four-year university degrees and adopted its present name. It is a member of the Independent Colleges and Universities of Florida and is accredited by the Southern Association of Colleges and Schools and the Association to Advance Collegiate Schools of Business . Its sports teams are known as the Jacksonville Dolphins. Wikipedia.

Bautista R.E.D.,Jacksonville University
Epilepsy and Behavior | Year: 2013

Purpose: The purpose of this study was to determine whether racial differences exist in the coping styles of individuals with epilepsy. Methods: This study utilized a survey of patients with epilepsy, including the Brief-COPE. Results: One hundred thirteen Caucasians and 70 African-Americans comprised the study population. On univariate analysis, annual household income (p. <. 0.01), receiving disability benefits (p. <. 0.01), and number of AEDs being currently used (p=0.04) significantly distinguished Caucasians from African-Americans. African-Americans reported higher utilization of religion (p. <. 0.01), denial (p. <. 0.01), emotional support (p=0.02), positive reframing (p. <. 0.01), and planning (p. <. 0.01) as coping reactions compared to Caucasians. Using ordinal logistic regression, the association between being African-American and the higher utilization of religion, positive reframing, planning, and denial as coping strategies remained statistically significant. Conclusion: Among individuals with epilepsy, African-Americans appear to utilize more engagement-type coping reactions when compared to Caucasians but also utilize more denial. © 2013 Elsevier Inc.

Ackerman M.B.,Jacksonville University
Orthodontics : the art and practice of dentofacial enhancement | Year: 2011

Removable retainer wear is most related to patient comfort and acceptance. Patient compliance is essential for retention and maintenance of the orthodontic treatment results. Even though patients are educated about the need for prolonged retention after active treatment and asked to sign informed consent regarding the risk of noncompliance (relapse) prior to treatment, most orthodontists would estimate that at least half of their teenage patients do not comply at optimal levels. The aim of the present study was to quantify teenage patient compliance with removable maxillary retention and compare actual usage vs prescribed usage between subjects who knew they were being monitored via an implanted microsensor in the retainer and those subjects who were unaware of any monitoring. The final sample consisted of 9 subjects in the test group (5 males and 4 females) and 10 subjects in the control group (4 males and 6 females). The evidence suggests that individuals who were made aware of the orthodontist's ability to monitor compliance wore the device for a significantly larger number of hours per day than those who were unaware of this fact. Patients reporting full usage of the retainer wore the appliance a mean of 4.3 hours more per day than those reporting less than full usage, holding all other variables constant. Patients who misrepresented their retainer use (reported full usage but wore the device less than 19 hours per day) wore the appliance a mean 12.4 hours less than the more honest patients who participated in the study.

Bates E.R.,University of Michigan | Lau W.C.,University of Michigan | Angiolillo D.J.,Jacksonville University
Journal of the American College of Cardiology | Year: 2011

Multidrug therapy increases the risk for drugdrug interactions. Clopidogrel, a prodrug, requires hepatic cytochrome P450 (CYP) metabolic activation to produce the active metabolite that inhibits the platelet P2Y 12 adenosine diphosphate (ADP) receptor, decreasing platelet activation and aggregation processes. Atorvastatin, omeprazole, and several other drugs have been shown in pharmacodynamic studies to competitively inhibit CYP activation of clopidogrel, reducing clopidogrel responsiveness. Conversely, other agents increase clopidogrel responsiveness by inducing CYP activity. The clinical implications of these pharmacodynamic interactions have raised concern because many of these drugs are coadministered to patients with coronary artery disease. There are multiple challenges in proving that a pharmacodynamic drugdrug interaction is clinically significant. To date, there is no consistent evidence that clopidogreldrug interactions impact adverse cardiovascular events. Statins and proton pump inhibitors have been shown to decrease adverse clinical event rates and should not be withheld from patients with appropriate indications for therapy because of concern about potential clopidogreldrug interactions. Clinicians concerned about clopidogreldrug interactions have the option of prescribing either an alternative platelet P2Y12 receptor inhibitor without known drug interactions, or statin and gastro-protective agents that do not interfere with clopidogrel metabolism. © 2011 American College of Cardiology Foundation.

Laparoscopic pancreaticoduodenectomy is a technically demanding procedure. In this video, we demonstrate the technical aspects of performing the procedure. In a 50-year-old male with ascending cholangitis, endoscopic retrograde cholangiopancreatography was unsuccessful, and percutaneous transhepatic cholangiography was carried out for biliary decompression. Endoscopic ultrasound plus fine-needle aspiration showed pancreatic head adenocarcinoma. The procedure was carried out using five trocars, and extensive lymphadenectomy was undertaken. The uncinate process was skeletonized off the superior mesenteric artery. The right lateral aspect of the superior mesenteric vein-portal vein confluence was involved with the cancer. The laparoscopic linear stapler was used to transect part of the vein en bloc with the specimen. All margins were negative and all the anastomoses were done using laparoscopic intracorporeal suturing. Operative time was 8 h 20 min, and hospital stay was 5 days. Final pathology was T3 N1 (one lymph node out of 40 was positive). Conclusion Laparoscopic pancreaticoduodenectomy can be performed safely in selected cases of pancreatic head cancer with vascular involvement. Skilled laparoscopic skills are necessary to execute such procedures safely. © 2014 Society of Surgical Oncology.

Our knowledge of the mechanisms of platelet-mediated thrombosis has increased dramatically over the last 40 years. This increased understanding has identified treatment strategies for acute coronary syndromes (ACS) by targeting key mediators of platelet activation and aggregation processes. Aspirin (acetylsalicylic acid) monotherapy improves patient outcomes by irreversibly inhibiting the cyclooxygenase (COX)-1 enzyme in the arachidonic acid pathway. The later-developed thienopyridines, prodrugs that irreversibly inhibit the P2Y12 receptor, and therefore adenosine diphosphate (ADP) binding, further enhance platelet inhibition and patient outcomes. The thienopyridine clopidogrel has been the standard of care, but it is limited by variable response and treatment failure. A more potent thienopyridine, prasugrel, requires fewer hepatic metabolic steps for activation, and elicits significantly improved outcomes for patients with ACS. The increased potency of prasugrel is associated with an increase in Thrombolysis in Myocardial Infarction (TIMI)-defined major bleeding compared with clopidogrel. Ticagrelor represents a new chemical class of agents called the cyclopentyltriazolopyrimidines. It interacts reversibly with the platelet P2Y12 receptor, and does not require metabolic bioactivation for activity. Data show a significant improvement in ischaemic outcomes, including mortality, for ticagrelor compared with clopidogrel, without an increase in overall major bleeding, although non-coronary artery bypass graft bleeding is increased. Glycoprotein IIbIIIa targeted agents (abciximab, tirofiban and eptifibatide) are also used in ACS patients undergoing percutaneous coronary interventions. These inhibitors utilize a different mechanism of action by preventing fibrinogen-mediated platelet aggregation. Other therapeutic strategies for platelet inhibition are being evaluated, including the investigative protease-activated receptor (PAR)-1 and thromboxane A2 antagonists. This review highlights the mechanisms of action of these agents, and the continuing evolution of ACS therapy. Adis © 2012 Springer International Publishing AG. All rights reserved.

Discover hidden collaborations